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SUMMARY
The focus in this thesis is on prognostic factors in primary biliary cirrhosis (PBC). The
patients who were subject of this study all came from a single Dutch centre and although the
methodology employed to reach conclusions could be sophisticated, the substrate most often
consisted ofbedside findings and routine laboratory investigations.
The main object of prognosis in this chronic disease is forecasting the interval to death,
enabling interventions at a timely interval before this ultimate event. Much can be leamed
from those who died from PBC or had PBC as a secondary cause of death and this thesis
therefore starts with an analysis of PBC mortality figures in The Netherlands.
In Chapter 1, mortality figures from The Netherlands Central Bureau of Statistics were
analysed for death from PBC (417 persons) and with PBC (179 persons), totalling 596
persons (6.3 per million inhabitants of 35 years and over). The female/male ratio was with
4.2, smaller than compared with the literature. In the South of the country there were
significantly fewer deaths and in the North significantly more. The median age class at death
was 70-74 and no person died below 35. In 1992, liver transplantation (LT) had nearly
eliminated death from PBC in the age category 35-59. It was concluded that mortality from
PBC mainly occurs in the old and very old, which asks for a more general approach and
management and that LT had been effective in eliminating death from PBC at younger age.
In Chapter 2, the mortality data were analysed for the secondary causes of death, including
diseases usually associated with PBC, cardiovascular risk and malignancies. The secondary
causes of death originated from the circulatory, digestive and respiratory tracts and from
malignancies. A 25-fold higher than expected incidence of hepatocellular carcinoma (more in
persons under 60) and a 5-fold increase in diseases ofthe musculoskeletal system was found.
There were no signifrcant differences for malignancies or for diseases of the circulatory
system, including ischaemic heart disease (which is important as hypercholesterolaemia is
common in PBC). It is concluded that the study of mortality data led to findings which are
important for diagnosis and management in the still living patients with PBC.
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ln Chapter 3, the Mayo model is validated in 83 Dutch PBC patients. In 1989, the Mayo
C'lipic developecl a prognostic model for PBC which is based on routinc clinicochemical
paraneters (serunt albumin, serurr bilirubin and prothrombin time), one clinical hnding
(oedema score) an<i age only. lt has bccome the most widespread prognostic model for PBC.
T5e Ma1,o rlodel proved able to predict sun'ival within lorv-, nredium- ar.rd high-risk score
grolps ancl testing of the inclividuai risk scores in a Cox regression rnodel sl.rowed excellcnt
rcsults. Plasn.ra sodium ald platelet count ."vere investigated for surv'ival predicting properties
in pBC: plasma so{ium faile<l and thrombocytes passed. In high-risk patients a combinatioll
of the Mayo Mode I and platelet count couid predict survival somewhat better than the original
Mayo lrodel. Using both the original and the modified models as mathematical background,
liyer transplantation (performed in a number of patients) was shown to have a beneficial effect
on survival. but the models could not be used to predict before LT the length of survival post-
transplantation. It is concluded that the Mayo model was successfully validated, and that the
predictir.rg role of platelet count should be fuíher investigated.
hl Chapter 4, a time-dependent Mayo model, based on updated risk score results in PBC
patients was developed to predict short term survival at any time in the course ofthe disease,
using tl.re prognostic Mayo variables of the latest patient visit. This was felt needed as the
Mayo rnodel ulderestimated survival in the high-nsk group of patients. In this study the
updated rlodel was tested using 1945 patient visits from 3i2 PBC patients admitted to the
Mayo Clinic and independently 481 intervals from the earlier mentioned 83 Dutch PBC
patients. The update model was superior to the original model for predicting shoÍ-term
survival in both patient sets. It was concluded from this cross-validated study that the Mayo
update t.nodel can be recommended for improving the accuracy of survival prediction during
the two ycars after a patient visit.
16 Chapter 5, the first occurrences of clinical findings (signs and major events), Mayo
survival probabilities as well as the course of four cirrhosis severity assessment scores (Mayo,
Campbell, pggh and Ascites/ Nutritional State (ANS)) were studied 16-0.5 years prlor to
cleath in 32 Dutch PBC patients dying from PBC. Eighty-four percent (n:27) experienced a
nrajor clinical event, always in the period 6 years (median 1) prior to death. Signs were
observecl for the first time as early as 14 years belore death but most often in the hnal ó
1.,ears. Thc prognosis of patients in whom a sign was detected and the more so in those rvho
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against estimated Mayo 50% survivai was concordant with a plateau phase from -16 to -7
years before death falling offfrom -6 to -0.5. The estirnated 50 %o survival rate in the period -6
to -0.5 years correlated with all severity assessment scores (Mayo best with Campbeli and
Pugh). Based on clinical findings and severity assessment scores it was concluded that a
steady state (lasting at least 10 years) was followed by a hnal phase (the last 6 years before
death), wliich rvas marked by the appearance of events, and worsening of severity assessment
scores which all showed a clear correlation to the Mavo survival estimates.
ln Chapter 6, the additional prognostic value of clinicochemical parameters and body
measurements was investigated in the 32 patients dying from PBC. Ery4hrocy.te sedimentation
rate and serum IgM were already elevated at the initial observation of all patients, indicating
that our observation period did not encompass early PBC. Several laboratory parameters
showed increased worsening in the last two years before death, which was coined the terminal
pliase. Sixty-sevcn ilems: clinicochemical variables, body measurement parameters, severity
assessment scores, first observations of signs and first occunences of major events were
analysed by time-dependent Cox regression analysis for prediction of survival and of major
events. Multivariate independent predictors of survival were for the steady state phase (-16 to
-7 years) Campbell score, temperature and platelet count, for the final phase (-6 to -0.5) Mayo
score and urinary sodium and for the terminal phase (-2 to -0.5) serum bilirubin and ANS-
score. Independent predictors for the first occurrence of events were for ascites: Mayo risk
score and plasma sodium, for hepatic encephalopathy: Mayo risk scorc, for upper
gastrointestinal bleeding (and separately variceal bleeding): whole blood water and for any
event: urinary sodium and serum IgA. It is concluded that four disease phases can be
identified: early PBC (not in our patients), steady state (up to six years before death), a final
phase (six years before death) and as part of this the terminal phase (the last two years).
Independent predictors of survival could be identified for all pirases present in our patients as
well as for the major clinical events.
In Chapter 7, the (additional) prognostic value of antimitochondrial antibody subtypes was
investigated in the 32 patients dying from PBC. Antimitochondrial antibodies are diagnostic
for PBC and it has been proposed that their subtypes (and subtype profiles) are indicators for
the progression of disease. A search for prognostic indicators of survival was done for the
wliole observation period, and the three disease phases (steady state, hnal and terninal)
separately. When only the 55 auto-antibody parameters were subjected to Cox regression,
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mtl l t ivanatc prcdictor in thc stcady state phase and thc f ina1 phase rvas M8 (Í-avourablc), over
thc *hole pcriod Nl2 and M8 (fal 'ourable) and in the temrrnal phase none. When the subtypes
l cre teste cl in cornbination with the cl inicochemical parameters, they (together r,vi th
cl inicocl 'ren'r ical paramcters) appeared in the mult ivariate analysis over the whole period (M2)
and the steady statc (M8) but not in the hr.ral and temrinal phases. In combination with the 67
clrnicocl 'remical ancl cl inical parameters, mitochondrial antibody subtypes or prof i les did not
ai lpear as precl ictors in the r.nult ivariate analysís in any phase of the disease. I t  was concludcd
that in this patient populat ion and study design, M2 and M8 subtypes l .rad prognostic
signrÍrcancc, but that the prognostic relevance of severity assessment variables and scores,
cl inical f indings and routine cl inicochemical laboratory parameters was greater.
In Chapter 8, the t irning of l iver transplantat ion in a group of 41 PBC patients was projected
on the tir.r.rclir.rc to cleatli of the 32 patients dying fron PBC, using thc clinical and laboratory
paramcters as describcd in prcvious chaptcrs. Thc LT t iming had been done on cl inical
judgernent. The mctirod uscd was to sl iderule thc variables and score results one year before
LT against the sanre clata 1-6 years beÍbre death. The best fit was for first occurrences of
n'ujor evcnts and for assessment scores between 1 year before LT and 2 years before death,
the differcnce being one ycar. This'"vas also reflected in the first occuÍrences of events wliich
all took place in the last 5 years belore LT, compared to ó years before death from PBC. The
laboratory results were inconclusive. The Mayo survival probabil i t ies 2 years before death
and 1 vear beÍbre LT did not differ between both groups and were too optimistic. It was
cor:Lclucled that clinical judgement liad been adequate and that in addition to surv'ival estimates
and scverity :rssessment scores, other parameters such as first occurrences of major events
shoLrld be takcn into account for the t imine of LT.
ln Chapter 9, the relat ions of plasma sodium and of whole blood - and plasma water to death
fior.n PBC wcre investigatcd in the 32 patients dying from PBC. A severely decreasecl plasma
sodiurn is knorvn to be associated with shortened survival (Nao<I30 mmol/ l :  'di lut ional '
hyponatraemia), but less is known about hydraemia as a prognostic factor. Over the wholc i6
ycar period before cleath, whole blood water, plasnra water and plasma sodium were
irrdependent prognostic indicators. The water and sodium observations of the 32 patients
clying fror.n PBC and the 41 LT patients then wcre pooled, and score ranges for plasma
sodium and wholc blood watcr were made, l-3 from better to worse. Between the 3 sodium




u i th h1,per
conclucied I
n  c l l -kno* r
Conclusiori
Prognostrcr
thc  c l in ic i r
probabil i t i r
inrportant
methocl. A
patlents \ \ '

































death or - in most instances - LT, all severity assessment scores, Mayo survival probabilities
and most laboratory parameters. Plasma sodium <130 was in a large minority not associated
with hyper\draemia and the term 'dilutional hyponatraemia' therefore is debatable. It was
concluded that hyperhydraemia was a progrostic factor in our patients with PBC and that the
well-known short survival in patients with severe hyponatraemia could be confirmed.
Conclusions.
Prognostication in primary biliary cirrhosis has reached a level of certainty that is helpful to
the clinician. Still, there are patients in whom severity assessment methods or survival
probabilities do not signal impending danger. This field should be investigated further. Some
important prognostic parameters are difficult to include for a general survival probability
method. An example is the very bad outlook for the relatively few, but easily identifrable
patients with a very low sodium. The shortened survival in hyperhydraemic PBC patients
should be validated. In the timing of liver transplantation, over-all clinical judgement proved
to be adequate.
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